ClinicalTrials.gov
public full text
Public Domain
Glucocorticoids and Bone in Graves' Ophthalmopathy
Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid. The investigators aim at investigating whether this treatment regimen also affects bone metabolism.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- 7 Day Continuous Parathyroid Hormone IV Infusion#846485
- Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy#1151543
- An in-depth examination of bone avascular necrosis and early-stage treatment modalities utilizing regenerative medicine.#631146
- Dextenza in Pterygium Surgery#1172401
- ADD-ON Study to Existing Hypoparathyroidism Studies#912120
Record · ID 1094129
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive